Net Income

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

With a €1.5B capital raise backed by governments and strategic giants, Eutelsat is fueling its unique hybrid satellite network to compete in the new space race.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

Malaysia's Treasure Global secures fresh capital, but a brutal market reaction and high cash burn raise questions about its super app's future.

A $277M secondary offering sees MIAX shareholders cash in, but the company itself isn't taking any money. Here’s what that says about its financial power.

An independent study shows Mesoblast’s cell therapy has superior remission rates over a market leader, hinting at a new standard of care and a big win for investors.

A new 'inspired by' fragrance brand is betting its vertically integrated model and aggressive pricing can break the industry’s century-old luxury spell.

Centrus Energy is building a key Ohio facility, the first step in a multi-billion dollar plan to end US reliance on Russian uranium for next-gen reactors.

AMC's key governance reforms failed despite 90% voter support, stymied by low turnout. Meanwhile, a major share increase passed. What does this mean?

Erie Indemnity boosts its dividend by 7.1%, but a deeper look reveals a unique and legally challenged fee structure driving its profitability.

Datavault AI is issuing a 'meme coin' to shareholders. Is this the future of corporate rewards or a regulatory tightrope walk with a speculative asset?

A new partnership between KBRA Analytics and Intex Solutions streamlines CMBS analysis, promising to enhance risk management in volatile economic times.

Zoetis boosts its dividend by 6%, but what does this move signal about the company's financial health and the booming global animal care market?

Tenaya Therapeutics unveils promising interim data for its ARVC gene therapy, TN-401, hinting at a potential cure and igniting investor interest.

BrightView Holdings declared its eighth straight cash dividend, a move signaling financial discipline even as it navigates revenue challenges and stock volatility.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

Dynex's routine dividend declaration reveals a complex strategy of risk management and capital allocation, offering a masterclass in navigating mREIT turbulence.

Excelerate Energy signals deep confidence with a new $75M share buyback, balancing shareholder rewards with an ambitious global expansion in the LNG market.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

Fast Track Group partners with CloudX to merge celebrity power with influencer trust. Can this hybrid model unlock profit in the complex APAC market?